CanSinoBio won the race when it obtained approval for the first inhaled COVID vaccine for public use. However, National Medical Products Administration of China restricted it to booster doses according to BBC.Com. Their reporter explains how the COVID nasal booster uses a harmless adenovirus as carrier. And that this contains the critical genetic code that trains the recipient’s immune system.
COVID Nasal Booster Adds Additional Immunity
COVID vaccines we have used to date in North America tend to focus on deep body infections. However, the new China inhaled vaccine is a fine mist that will add protection to the inner lining of the nose and upper airways.
That’s because these are the areas where COVID-19 typically enters the body. Therefore the CanSinoBio vaccine manufacturer says its Convidecia product provides ‘good protection after just one breath’.
Pharmaceutical Technology says the method uses a nebuliser to change liquid into an aerosol for inhaling through the mouth. This is a non-invasive way to administer the vaccine without using a needle, and therefore quick and fast.
More Information About the Booster and Its Trials
The China nasal booster entered clinical trials after co-development with Beijing Institute of Biotechnology. The results indicated it could ‘prompt robust cellular, humoral and mucosal immunity to attain triple protection’. As well as ‘control the virus spread and the infection’ according to the company press release we link to below.
The CanSinoBio company already manufactures several other vaccines, and has an established global distribution network. It obtained emergency listing for the new product from World Health Organization in May 2022.
World Health Organization based their decision on scientific evidence the company submitted. As well as data from a Phase III clinical trial which evaluated safety and efficacy. We wish CanSinoBio a successful rollout of their most interesting innovation.
Breaking News
Detecting COVID in a Human Voice With A.I.
Chengdu Where People Still Go Shopping Daily
